A recent study shows that a gamechanger drug called Fevipiprant promises to lower patients’ risks of suffering an asthma attack and being admitted to a hospital. This is the first time a drug reducing airway smooth muscle mass—a key clinical indicator of disease severity that increases the likelihood of more frequent asthma attacks and even deaths—has been reported. Along with Rod Smallwood, fellow of the British Royal Academy of Engineering, I developed computer models that allowed us to simulate results from a Phase 2 clinical trial—to predict therapy outcomes in patients. The original trial was led by Christopher Brightling, clinical professor in respiratory medicine at the University of Leicester and the principal co-ordinator of the European Lung Foundation AirPROM.

Read the full article here, or you can also view the scientific article by clicking here!

Leave a Comment